1	Full title: Aberrant stromal tissue factor and mycolactone-driven vascular permeability,
2	exacerbated by IL-1 β , orchestrate pathogenic fibrin formation in Buruli ulcer lesions
3	
4	Short title: Endothelial dysfunction in Buruli ulcer skin lesions
5	
6	Louise Tzung-Harn Hsieh ¹ , Scott J Dos Santos ^{1,#a} , Joy Ogbechi ^{1,#b} , Aloysius D. Loglo ^{1,#c} ,
7	Francisco J. Salguero ² , Marie-Thérèse Ruf ^{3.4} , Gerd Pluschke ^{3.4} , and Rachel E. Simmonds ^{1,*}
8	
9 10 11	¹ Department of Microbial Sciences, School of Bioscience and Medicine, University of Surrey, Guildford, United Kingdom
12	² Public Health England, Manor Farm Road, Porton Down, Salisbury, United Kingdom
13	
14	³ Swiss Tropical and Public Health Institute, Basel, Switzerland
15	Alleinersity of Decel Decel Quiterrales d
16 17	* University of Basel, Basel, Switzerland
18 19	^{#a} Current address: Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
20	
21 22	^{#b} Current address: Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford, United Kingdom
23	
24 25	^{#c} Current address: Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
26	
27	* Corresponding author, email: <u>rachel.simmonds@surrey.ac.uk</u>

29 Author contributions

- 30 Conceptualization: LTHH FJS RES. Performed the experiments: LTHH JO ADL MTR.
- Analysed the data: LTHH SJDS JO FJS MTR RES. Contributed materials: MTR GP. Wrote
- 32 the manuscript: LTHH SJDS FJS MTR RES. Funding acquisition: GP RES.

34 Abstract

The neglected tropical disease Buruli ulcer, caused by Mycobacterium ulcerans infection, 35 displays coagulative necrosis in affected skin tissues. We previously demonstrated that 36 exposure to the *M. ulcerans* exotoxin mycolactone depletes the expression of thrombomodulin 37 38 and impacts anticoagulation at the endothelial cell surface. Moreover, while widespread fibrin 39 deposition is a common feature of BU lesions, the cause of this phenotype is not clear. Here, we performed sequential staining of serial tissue sections of BU patient biopsies and unbiased 40 analysis of up to 908 individual non-necrotic vessels of eight BU lesions to investigate its 41 42 origins. Most vessels showed evidence of endothelial dysfunction being thrombomodulinnegative, von Willebrand factor-negative and/or had endothelium that stained positively for 43 tissue factor (TF). Primary haemostasis was rarely evident by platelet glycoprotein CD61 44 staining. Localisation of TF in these lesions was complex and aberrant, including diffuse 45 46 staining of the stroma some distance from the basement membrane and TF-positive infiltrating cells (likely eosinophils). This pattern of abnormal TF staining was the only phenotype that 47 was significantly associated with fibrin deposition, and its extent correlated significantly with 48 the distance that fibrin deposition extended into the tissue. Hence, fibrin deposition in Buruli 49 50 ulcer lesions is likely driven by the extrinsic pathway of coagulation. To understand how this could occur, we investigated whether clotting factors necessary for fibrin formation might gain 51 access to the extravascular compartment due to loss of the vascular barrier. In vitro assays 52 using primary vascular and lymphatic endothelial cells showed that mycolactone increased 53 54 the permeability of monolayers to dextran within 24 hours. Moreover, co-incubation of cells with interleukin-1 β exacerbated mycolactone's effects, nearly doubling the permeability of the 55 monolayer compared to each challenge alone. We propose that leaky vascular and lymphatic 56 57 systems are important drivers of extravascular fibrin deposition, necrosis and oedema 58 frequently seen in Buruli ulcer patients.

59

60 Author Summary

To date, the debilitating skin disease Buruli ulcer remains a public health concern and financial 61 burden in low or middle-income countries, especially in tropical regions. Late diagnosis is 62 frequent in remote areas, perhaps due to the painlessness of the disease. Hence patients 63 64 often present with large, destructive opened ulcers leading to delayed wound closure or even 65 lifelong disability. The infectious agent produces a toxin called mycolactone that drives the disease. We previously found evidence that the blood clotting system is disrupted by 66 mycolactone in these lesions, and now we have further explored potential explanations for 67 68 these findings by looking at the expression of coagulation regulators in BU. In detailed analysis of patient skin punch biopsies, we identified distinct expression patterns of certain proteins 69 70 and found that tissue factor, which initiates the so-called extrinsic pathway of blood clotting, is 71 particularly important. Mycolactone is able to disrupt the barrier function of the endothelium, 72 further aggravating the diseased phenotype, which explains how clotting factors access the 73 tissue. Altogether, such localised hypercoagulation in Buruli ulcer skin lesions may contribute to the development of the lesion. 74

75 Introduction

Buruli ulcer (BU) is a neglected tropical disease, resulting from a subcutaneous infection with 76 Mycobacterium ulcerans, with approximately 2700 new cases reported globally in 2018 77 according to the latest update from World Health Organization (WHO) [1]. BU endemic areas 78 79 include West and Central African countries as well as Australia; globally over 30 countries 80 have reported cases with estimated prevalence ranging from 3.2-26.7 BU cases per 10,000 population [2, 3]. BU presents in various forms such as nodules, plaques, ulcers and oedema 81 [2]. In late diagnosed cases, necrotic skin lesions and soft tissue destruction can extend to 82 83 15% of body surface area, which may cause lifelong disability [4]. This debilitating skin condition can be treated with dual anti-mycobacterial antibiotics, sometimes alongside surgical 84 removal of infected skin tissues [5]. Yet delayed wound healing rate remains a critical issue, 85 especially in patients bearing large, open lesions [6]. 86

87

Histopathological analyses of BU patient biopsies reveal unique features of *M. ulcerans* infections [7]. For instance, the coagulative necrosis seen in BU lesions displays a relative paucity of leukocytic infiltration close to the bacilli themselves [7, 8]. Instead, neutrophils are seen in the peripheral areas [9] and necrotic tissues often extend some distance from the site of mycobacterial colonisation [7, 10]. Both characteristics are caused by the lipid-like exotoxin produced by *M. ulcerans*, mycolactone [10, 11], which is synthesised by polyketide synthases encoded on a megaplasmid, pMUM001 [12].

95

96 Mechanistically, mycolactone causes cell cycle arrest in G_0/G_1 and subsequent progression 97 to apoptosis after 48-72 hours, depending on cell type [10, 13]. Mycolactone can potentiate 98 an integrated stress response via eIF2 α phosphorylation and ATF4 activation [14, 15]. In 99 addition, mycolactone has immunosuppressive effects on the maturation or functions of 100 macrophages, dendritic cells and T cells [16-20]. All these activities can now be attributed to

101 mycolactone's inhibitory effect on Sec61 translocon [21, 22], which affects co-translational 102 translocation of proteins into the endoplasmic reticulum (ER) [21, 23-26]. This blockade leads 103 to protein translation in the wrong cellular compartment followed by their proteasomal 104 degradation [21] and activation of autophagy pathways [14, 27]. Cells carrying mutations in 105 the gene encoding Sec61 α are resistant to mycolactone-driven cytotoxicity, supporting this as 106 the primary target of mycolactone, at least at lower doses [14, 22, 23].

107

108 Mycolactone targeting of the Sec61 translocon is seen in various cell types, including 109 endothelial cells, which regulate many physiological functions related to blood vessel homeostasis [21, 28]. Normally, endothelial cells form a monolayer that lines the lumen of 110 111 blood vessels or form the capillaries. This semi-selective barrier controls the passage of small molecules and white blood cells into and out of the bloodstream [29, 30]. When blood vessels 112 are injured, platelets rapidly attach to the damaged sites on the endothelium via its binding 113 114 partner von Willebrand factor (vWF) [29, 31]. Secondarily to platelet plug formation, coagulation reinforces the plug by producing a fibrin mesh to hold it in place [29]. Fibrin clot 115 formation can be triggered by both contact activation on a negative-charged, damaged surface 116 or via the tissue factor (TF)-initiated extrinsic coagulation pathway. TF exposed from the sub-117 endothelium binds to blood-borne factor VIIa and other clotting factors, leading to thrombin 118 activation and consequent processing of fibrinogen to fibrin [31]. These haemostatic pathways 119 are regulated by the endothelium through its expression of specific molecules that function in 120 anticoagulant pathways [30]. These include thrombomodulin (TM) and the endothelial cell 121 protein C receptor (EPCR) that activate the protein C anticoagulant pathway [30, 32], tissue 122 factor pathway inhibitor (TFPI) that supresses the factor VIIa-TF complex and free factor Xa 123 activity [33], and heparan sulphate proteoglycans within the glycocalyx that bind antithrombin 124 to directly inhibit thrombin [34]. 125

127 We previously showed that mycolactone depletes thrombomodulin and the EPCR from 128 primary human dermal microvascular endothelial cells (HDMECs) [28]. Reduced 129 thrombomodulin staining was also seen in clinical specimens of BU where it was associated 130 with fibrin deposition, itself strongly correlated with tissue necrosis [28]. While we did consider 131 the dermis and subcutis separately, we acknowledged challenges in the analysis due to tissue 132 heterogeneity. In order to overcome these challenges and to better understand the role and origin of fibrin deposition in BU lesions, originally reported in the mid-20th Century, we 133 134 performed immunohistochemical staining of serial tissue sections of BU patient skin biopsies 135 for vascular and coagulation biomarkers. This more comprehensive analysis now shows an unexpected paucity of platelets, even in areas with extensive fibrin deposition, and widespread 136 endothelial dysfunction. Fibrin deposition is explained by abnormal expression patterns of TF, 137 implicating the involvement of extrinsic clotting pathway. The largest effect was driven by 138 139 vessels that displayed TF staining at significant distance away from the basement membrane. In parallel experiments, our *in vitro* data showed that mycolactone increased the permeability 140 of endothelial monolayers. Taken together our findings suggest that the vessels in BU lesions 141 may become "leaky" during infection due to loss of the endothelial barrier integrity, and that 142 143 this drives fibrin formation.

144 **Results**

Immunostaining was performed on serial skin biopsy tissue sections from 8 untreated, 145 laboratory confirmed BU patients (6 with ulcerative lesions and 2 with plaque, covering 3 WHO 146 categories; Table 1 and S1 Fig). Repeat staining for several markers on different sections of 147 148 the same punch biopsies in Ogbechi et al., 2015 [28] revealed that the pathology of Buruli 149 ulcer is highly focal, even within these small 4mm samples of infected skin (S2A Fig). Hence, serial sections minimise drift throughout the biopsy sample and allow the tracking of individual 150 151 vessels within the skin (S2B Fig) between the sections. The sections were stained in the 152 following order: haematoxylin-eosin, fibrin, thrombomodulin (CD141), CD61, CD31 (Platelet endothelial cell adhesion molecule; PECAM-1), smooth muscle actin (SMA), Ziehl-Neelsen, 153 TF and vWF. Regions of BU punch biopsy samples containing as many non-necrotic blood 154 vessels as possible were defined by a pathologist prior to the start of analysis. This decision 155 156 was made based on the number of blood vessels present that were positive for SMA or CD31 and whether there was any submacroscopic appearance of coagulative necrosis present in 157 the corresponding H&E section. These "pre-defined" regions (see methods) are outlined in red 158 in S1 Fig; nine areas were within the dermis and one area was located in the subcutis. 159 160 Quantitative analysis concerned all identifiable vessels within these regions, regardless of whether nearby tissue displayed local signs of necrosis, in order to facilitate an unbiased 161 analysis. Qualitative comparative analysis of the novel biomarkers not yet explored in BU 162 (CD61, vWF and TF) was also performed across the whole biopsies, including areas that were 163 164 highly necrotic. Acid fast bacilli were only visible in the sections from two of the patients (S2C Fig), therefore we do not report analysis of the coincidence of Ziehl-Neelsen staining further. 165

166

Vasculopathy is evident in non-necrotic vessels of Buruli ulcer lesions

First, we closely analysed the phenotype of blood vessels in the defined regions of BU lesions
using three well-known perivascular and/or endothelial cell markers: CD31, SMA and

thrombomodulin. Since our previous studies showed that both thrombomodulin and, to a lesser extent, CD31 could be depleted by mycolactone exposure [28], we took a conservative approach and identified vessels which stained positively for SMA, or at least one of thrombomodulin and/or CD31. Using this approach, a total of 908 vessels were identified in the pre-defined regions of the eight patient samples (median of 92.5 vessels per patient sample, range 18-253).

177

When vessels were categorised according to the expression of these three markers (any level 178 of positive staining), thrombomodulin presence was found to vary widely, regardless of the 179 180 lesion type or WHO Category. All the vessels in the pre-defined region of one patient displayed 181 were TM⁺ (Fig 1A), although for this patient the pre-defined region was very small and contained only 18 vessels (S1 Fig). In contrast, two patients had few vessels expressing 182 thrombomodulin in the analysed areas, while other patients' samples showed intermediate 183 184 degrees of positive staining (Fig 1A). Overall, in the pre-defined regions containing nonnecrotic vessels, only 299 out of 908 (32.9%) had normal staining (TM⁺ CD31⁺ SMA⁺). The 185 remaining vessels lacked one or more of the expected vessel markers, with the most common 186 phenotypes being TM⁻CD31⁺SMA⁺ (37.4%) and TM⁻CD31⁻SMA⁺ (18.7%). Some of the singly 187 positive SMA structures could potentially be sweat glands with vessel-like morphology. 188 However, even if this is the case for a proportion of these solely SMA⁺ structures, the data 189 suggests a general vasculopathy in these BU lesions that precedes the emergence of 190 coagulative necrosis. 191

192

In order to understand whether the previously described association between thrombomodulin depletion and fibrin deposition [28] is functionally linked, fibrin deposition was scored for each identified vessel in the defined regions, according to its degree of extension. Here, 852 vessels were trackable in analysed areas of tissue sections stained with fibrin, since not all vessels identified above could be found in subsequent sections. As reported previously [28], fibrin

198 staining was seen across the biopsies, both in the defined regions and in highly necrotic areas 199 but varying in intensity and extent for each patient (S1 Fig). The fibrin was mostly evident as 190 tissue deposition surrounding, rather than in, blood vessels (298 vs. maximum 20 vessels in 191 the defined areas).

202

Scoring of the fibrin disposition around 329 TM⁺ and 523 TM⁻ vessels (where 0 is no staining, 203 and 3 is fibrin evident continuously for >30 µm from the vessel) showed thrombomodulin 204 205 expression had no overall impact on fibrin levels (chi² vs normal staining pattern P = 0.2007, 206 Fig 1B). Hence, thrombomodulin depletion itself does not seem to be a good predictor of local 207 fibrin deposition. However, while most vessels were fibrin-negative, in vessels lacking 208 thrombomodulin expression the proportion with the highest fibrin score was increased compared to TM⁺ vessels (13.0 vs. 7.3%, Fig 1B). Moreover, the fibrin intensity within 20 µm 209 of vessels lacking TM expression was much more variable than those where TM was detected 210 211 (up to 79.0 vs. 45.8%, Fig 1C), suggesting the loss may aggravate fibrin formation in certain subgroup(s) of vessels. This is borne out by comparing the intensity of staining in fibrin-positive 212 vessels, where TM⁻ vessels had significantly higher levels of fibrin within 20 µm. 213

214

Primary haemostasis plays only a minor role in BU skin lesions, perhaps due to mycolactone-depletion of von Willebrand factor from endothelial cells

Since loss of thrombomodulin does not explain all the fibrin disposition seen in BU patient lesions, other pathways that could lead to fibrin formation were explored. First, we examined the localisation of molecules involved in primary haemostasis [30]. vWF is the primary component of Weibel–Palade bodies, secretory granules that are released from endothelial cells in response to activation or injury [35]. In healthy skin, vWF was present in endothelial cells lining blood vessels as expected [36] (Fig 2A1-2 and S3A Fig). As others have observed [37, 38], there is a relatively high stromal background for vWF staining due to its presence in

serum. By contrast, in BU lesions, detection of endothelial vWF was frequently reduced (Fig
2B1, black arrowheads) or staining was seen in the intravascular space instead (Fig 2B1-2,
black stars); rarely, vWF remained detectable in the endothelium (Fig 2B3, black arrow).

228

One of vWF's primary roles is to capture activated platelets, thus providing a rich negatively
charged surface for amplification of the blood coagulation cascade leading to fibrin formation.
Activated platelets express platelet glycoprotein IIb/IIIa (CD41/CD61), as their main receptor
for vWF and fibrinogen, and here we examined the expression of CD61, also known as integrin
β3 [39]. Surprisingly, considering the wide abundance of fibrin in the lesion, very little CD61
staining was seen in BU lesions (Fig 2B4 and S1 Fig), even in areas with coagulative necrosis.
This suggests a minor role, if any for primary haemostasis in lesion formation.

236

To consider this more closely, we analysed the colocalisation of CD61 and vWF in BU patient vessels. In the defined regions (Fig 2C1-6, 2D1-6), CD61 and vWF were barely detectable in vessels, despite strong fibrin staining in the vicinity (Fig 2C4 and 2D4, blue and purple arrows). In vessels that were positive for of least one of SMA, CD31 or thrombomodulin, none stained positively for CD61. In necrotic regions in the subcutis, CD61 staining was occasionally seen in areas where fibrin deposition was evident, in vessels that were CD31⁺ and TM⁻, colocalising with vWF (Fig 2E1-6, red arrows).

244

We have already shown that platelet activation is not directly affected by mycolactone [28], and the CD61 presence did not correlate with vWF in non-necrotic vessels. Therefore, we postulated that this might be due to mycolactone-dependent depletion of vWF from endothelial cells, and there is some evidence to support this from these BU patient samples. Of 734 trackable vessels in defined regions in BU lesions, only 24.8% retained a normal expression pattern, with their endothelial monolayer stained positively for vWF (Fig 2B3 and 2F upper

251 panel). Instead, nearly half (47.4%) had completely lost vWF staining (vWF⁻) (Fig 2B1, 2C6, 2D6 and 2F upper panel). Intriguingly, 204 vessels (27.8%) displayed vWF staining within the 252 lumen of microvessels, in the intravascular space (Fig 2B1-2 and 2F upper panel). This pattern 253 of staining was particularly evident in BU patient punch biopsies in which the pre-defined areas 254 255 were heavily infiltrated with immune cells (S1 Fig, outlined in blue), representing 52.5% of such vessels (Fig 2F, lower panel). However, fibrin scores were similar across all three 256 phenotypes of vWF expression in vessels (chi² vs normal staining pattern P = 0.2882 and 257 0.1280 for intravascular and vWF-, respectively Fig 2F), suggesting that none of these 258 259 phenotypes are directly related to fibrin formation.

260

Since vWF enters Weibel-Palade bodies via the secretory pathway and should be a Sec61-261 dependent protein [35], we reasoned that the widespread depletion of vWF in BU lesions might 262 be related to the ability of the diffusible exotoxin mycolactone to inhibit the Sec61 translocon. 263 264 Hence, we visualised vWF in cultured primary HDMECs and human umbilical vein endothelial cells (HUVECs) by immunofluorescence (Figs 2G and S3B Fig). Although the amount of vWF-265 positive granules (presumptive Weibel-Palade bodies) varied from cell to cell, these were 266 greatly reduced after 24 hours exposure to mycolactone (Fig 2G). Furthermore, when we 267 quantified the level of vWF in conditioned medium from HDMECs by enzyme-linked 268 immunosorbent assay (ELISA), both basal and thrombin-induced vWF secretion was almost 269 completely abolished following mycolactone exposure (Fig 2H). 270

271

Extravascular tissue factor within BU lesions correlates to pathogenic fibrin deposition

Another potential trigger for fibrin generation is activation of the extrinsic coagulation cascade, initiated by TF. In the skin of healthy individuals, normal TF staining is found only in the epidermis and the adventitia of larger (but not smaller) blood vessels as expected (Fig 3A1-2 and S4A Fig). This highly restricted expression pattern is vital to maintain intravascular fluidity,

278 due to its ability to rapidly catalyse activation of the coagulation cascade by binding Factor VII/VIIa. In BU patient lesions, TF staining was not confined to the sub-endothelium and was 279 280 instead seen within the tissues in a complex, highly variable pattern between patients. For example, in one patient, TF was present at the edge of damaged area (S4C Fig) where 281 282 extravasated erythrocytes had accumulated. Abnormal TF staining fell into one of four main 283 categories. First, staining outside of the vessel basement membrane (BM) of larger vessels 284 (Fig 3B5 and 3C5, red arrows). Second, in presumptive infiltrating cells, either demonstrating 285 granular intracellular staining (Fig 3D5 and S4B Fig, black arrows) or intensively throughout 286 each cell (Fig 3E5, black arrows). This pattern of staining was seen in both necrotic and in 287 defined regions, and in the latter case was in regions that appeared to contain eosinophils 288 based on Haematoxylin and eosin (H&E) staining (Fig 3E3, black arrowhead). Third, TF staining was found within the endothelial cells lining smaller vessels (Fig 3F5, orange arrow), 289 290 which do not normally express this receptor. Lastly, some vessels contained some structures within the vessel lumen that could not be identified, yet stained strongly for TF (Fig 3G5, purple 291 arrows). Approximately one quarter of vessels with this phenotype were in infiltrated regions 292 (Fig 3G3). 293

294

295 With respect to TF-positive presumptive-infiltrating cells, these were observed within tissue 296 rather than close to vessels. Granular intracellular staining was seen in 5 of the 8 BU patient biopsies, almost exclusively in the defined regions where they were between 2.2-89.9 µm 297 298 away from the vessel BM. In most of these patients (4 out of 5) it occurred in areas displaying fibrin deposition (compare Figs 3D4 and 3D5). Infiltrating cells displaying intensive TF-positive 299 staining throughout each cell body were seen in 6 of the 8 BU biopsies and always in regions 300 of fibrin accumulation. This phenotype was more common in the necrotic subcutis (5 patients). 301 In the one patient where it was seen in a defined region, the cells were 17.1-120.9 µm away 302 303 from the vessel BM.

305 Vessels in defined regions were tracked and classified according to their TF expression patterns. Of 830 trackable vessels, 18.2% showed normal TF expression in the adventitia, 45 306 (5.4%) showed TF staining outside of the vessel BM, within the skin tissue, 63.3% displayed 307 abnormal TF staining in the vessel endothelium, and 13.1% showed TF within the vessel 308 309 lumen (Fig 3H). All abnormal expression patterns were associated with an increased chance of having the highest fibrin score. While this was not significantly different for vessels where 310 TF staining was seen in the lumen (chi² vs normal staining pattern P = 0.5901), it was distinct 311 in vessels where the endothelium was TF⁺ (chi² vs normal staining pattern P = 0.0014). Most 312 313 strikingly, whilst being relatively rare in the defined regions, vessels that displayed TF staining outside of BM were significantly more likely to have fibrin deposited in the surrounding tissue, 314 (chi² vs normal staining pattern P < 0.0001, Fig 3H) and more likely to have fibrin that extended 315 further from the vessel (82.22% exhibiting the highest fibrin score). Notably the coincidence of 316 317 fibrin and TF outside the BM was often found where there were local signs of tissue necrosis by H&E staining (e.g. Fig 3C3), suggesting that fibrin-deposition may cause result directly in 318 necrosis, presumably due to ischaemia. 319

320

Mycolactone reduces the expression of tissue factor pathway inhibitor in endothelial cells

The interaction between TF and the 50 kDa blood-borne factor VIIa, and the subsequent 323 324 triggering of the coagulation cascade leading to fibrin formation is normally prevented by a 325 functional endothelial barrier which segregates bloodstream from the TF-containing subendothelium [30]. Normally, TF/factor VIIa activity is suppressed by TFPI, which is mostly 326 expressed by vascular endothelium and megakaryocytes [33]. Endothelial cells predominantly 327 328 express the membrane-associated TFPI splice variant lacking both the C-terminus and the third Kunitz-type inhibitory domain (isoform β), but also express full-length TFPI (isoform α). 329 Upon stimulation or heparin infusion, TFPIa, bound to cell-surface glycosaminoglycans 330 through its C-terminus, can be secreted rapidly [40]. As fibrin deposition was found in BU 331

332 affected tissues and correlated to TF seen outside of vessel BM, we wondered whether TFPI 333 expression might be affected by mycolactone. As we were unable to test this in the biopsies themselves, we investigated this in vitro. TFPI was rapidly depleted from HDMECs in response 334 to mycolactone exposure with a decrease detectable after 8 hours by Western blot (Fig 4A); 335 336 given that TFPI α and β have different levels of glycosylation and migrate with similar molecular mass on sodium dodecyl sulfate polyacrylamide gel electrophoresis [41], we couldn't 337 distinguish between these isoforms. Quantification of this data demonstrated a 57.4% 338 339 reduction of total TFPI after 8 hours of mycolactone exposure and further to 88.3% after 340 24hours (Fig 4A). A similar decline was seen in conditioned medium, where the amount of TFPI secreted by HDMEC over 24 hours reduced from 4.59±0.18 to 0.74±0.13 ng/mL (Fig 341 4B). 342

343

Mycolactone-dependent vascular permeability as a potential driver of coagulopathy in Buruli ulcer lesions

Taken together the data from BU punch biopsies suggests that the expression of haemostatic 346 347 markers on the vessel endothelium is not a reliable predictor of fibrin deposition close to that vessel. Instead, fibrin deposition in the tissue seems to arise locally and driven by TF 348 expression that is uncontained within the stroma. To examine how uncontained TF may impact 349 fibrin deposition in such a distinct phenotype, the staining intensity of TF and fibrin were 350 351 quantified and the distance of the TF signal from the vessel BM were measured in these same 352 vessels. There was no correlation between fibrin and TF staining intensity within 20 μ m (r = -0.1623, P = 0.2869) (Fig 5A). However, there was a positive correlation (r = 0.2981, P =353 0.0467) between fibrin intensity and the distance of TF⁺ signal from the same analysed vessel 354 355 BM (Fig 5B).

356

357 Generation of fibrin within tissue, a substantial distance away from vessels, resulting from 358 extrinsic coagulation pathway activation would require large plasma glycoproteins to gain

359 access to the stromal compartment. We therefore asked whether mycolactone might induce changes to vascular permeability that could lead to a breakdown of vessel integrity in vitro. 360 Hence, we evaluated the effect of mycolactone on the permeability of HDMEC monolayers to 361 70 kDa FITC-labelled dextran in a transwell system. In line with our hypothesis, exposure to 362 363 10 ng/mL mycolactone for 24 hours increased the permeability of the monolayer to 33.1±6.2% 364 of the value seen when cells were completely absent from the transwell (Fig 5C), equivalent to around one-third of that seen with interleukin-1 β (IL-1 β), a known inducer of vascular 365 366 permeability [42].

367

368 We also wondered whether this mycolactone-dependent increase in permeability might extend 369 to the lymphatic system, since BU can sometimes have an oedematous presentation. In human dermal lymphatic endothelial cells (HDLECs), a subpopulation of endothelial cells that 370 actively participate in fluid balance and transport [43, 44], this phenotype was even more 371 372 apparent. HDLECs and HDMECs had comparable half maximal inhibitory concentration to mycolactone (around 0.67 ng/mL, S5 Fig), but the response of lymphatic endothelial cells to 373 mycolactone was more pronounced. Exposure to 10 ng/mL mycolactone for 24 hours 374 increased the permeability of the monolayer to 68.6±19.8% of the value seen in empty wells 375 (Fig 5D). In the same time window, 2.5 ng/mL mycolactone could potentiate this effect but to 376 a lesser degree (26.7±2.8%, Fig 5D). 377

378

IL-1β aggravates mycolactone-driven endothelial dysfunction

Recent work showed that IL-1 β can be induced by mycolactone-containing microvesicles and is found in *M. ulcerans*-infected tissues [45]. Since IL-1 β has been long-known to repress thrombomodulin expression in endothelial cells by a transcriptional mechanism [46], and also induces vascular permeability [42], we wondered whether the presence of this alarm cytokine might exacerbate the effect of mycolactone on the microvasculature. First, we addressed

386 whether mycolactone's ability to supress thrombomodulin expression in primary endothelial cells might be influenced by IL-1β, by exposing cells to a range of concentrations of 387 mycolactone and/or IL-1B. As expected, exposure to either 10 ng/mL IL-1B or 2.5 ng/mL 388 mycolactone alone for 24 hours led to a significant depletion in thrombomodulin protein level 389 390 in both HDMECs (Fig 6A) and HDLECs (Fig 6B). Similar to our observations regarding vascular permeability, lymphatic endothelial cells were more sensitive to both stimuli, with 391 >50% reduction in the presence of 0.6 ng/mL IL-1 β (*P* = 0.0132) or 1.25 ng/mL mycolactone 392 393 (P = 0.0004) (Fig 6B). Remarkably, this downward trend was more evident when the 394 endothelial cells were co-exposed to non-saturating amounts of both agents (Fig 6A and B). 395 For example, in HDMEC, while each stimulus alone resulted in ~55-75% depletion of 396 thrombomodulin expression, it was barely detectable in endothelial cells exposed to both 2.5 ng/mL mycolactone and 10 ng/mL IL-1β. In HDLEC, the combination of 0.625 ng/mL 397 398 mycolactone and 0.6 ng/mL IL-1 β suppressed thrombomodulin expression to the same extent as 10 ng/mL IL-1 β . These effects appear to be additive rather than synergistic. 399

400

Since the additive effect was particularly evident in HDMECs, we investigated whether it might 401 also influence vascular permeability in these cells. Here, we used a lower dose of IL-1 β , which 402 only slightly increased the permeability of monolayer after 24 hours (7.66±3.89% of the value 403 seen in an empty well, Fig 6C). Mycolactone had a dose-dependent effect on vascular 404 permeability as before, and the additive effect of IL-1β was evident when there was 5 ng/mL 405 mycolactone, increasing the permeability significantly from 17.58±7.57% to 44.62±9.65% (P 406 = 0.0021 vs. DMSO; P = 0.0268 vs. mycolactone alone). This data suggests that even low 407 amounts of IL-1^β in infected tissues might have a further negative impact on haemostatic 408 409 status and endothelial monolayer integrity where trace amounts of mycolactone are present.

410 **Discussion**

Coagulation is often considered as a frontline host defence response to infection due to 411 trapping of invading bacteria clots [47]; however, some pathogens develop strategies to 412 bypass or utilise clot architecture to gain access to host resources. For example, Streptococci 413 414 generate streptokinase, a plasminogen activator mimic, that promotes fibrinolysis and thus 415 has a positive impact on bacterial metastasis [48]. Coagulase-positive staphylococci, on the other hand, produce coagulase, which rapidly depletes fibrinogen from the plasma and blunts 416 417 the phagocytic activity of neutrophils [49]. Malaria-infected erythrocytes cause the loss of 418 EPCR and thrombomodulin in brain vessels, leading to subsequent fibrin deposition within the 419 microvasculature [50], which impacts the severity of cerebral malaria [51]. In the case of BU, the skin lesions exhibit large-scale coagulative necrosis in the subcutaneous regions, a distinct 420 pathological phenotype, which has been long associated with the biological effects of the 421 422 exotoxin mycolactone as it diffuses through the infected tissue [52].

423

424 Cumulative reports with in vitro or in vivo assays have addressed how cell death can be potentiated in response to mycolactone, either directly via the activation of caspase-3, 425 426 caspase-9 [53] or Bcl-2-like protein 11 [54] with resultant apoptosis, and/or via an integrated 427 stress response leading to ATF4 activation [14, 15]. These pathways may also involve disruption of actin cytoskeleton [55]. More recently an indirect mechanism was proposed, via 428 mycolactone's Sec61-dependent influence on coagulation control and resultant tissue 429 ischemia [28]. However, to what extent coagulation is dysregulated in BU has been unclear. 430 This present work demonstrates several abnormal phenotypes for haemostatic proteins in the 431 dermal microvasculature of BU patients that includes: 1) loss of key endothelial proteins such 432 as the endothelial adhesion molecule CD31, the anticoagulant thrombomodulin, and the 433 434 platelet binding partner vWF, and 2) highly abnormal expression patterns of TF that suggest a loss of containment. These changes likely underpin the pathogenic fibrin deposition seen in 435 the skin lesions and imply that infection with *M. ulcerans* may cause a localised, disturbed 436

haemostatic status. This conclusion is reinforced by *in vitro* data using primary endothelial
cells, in which we show that mycolactone can potentiate vascular and lymphatic hyperpermeability. Moreover, mycolactone limits the expression, and secretion of, vWF and TFPI.

440

441 Mechanistically, a combination of mycolactone's action at the Sec61 translocon, and increased local concentration of IL-1β, likely explains the endothelial dysfunction seen in BU. 442 Like the single-pass type I membrane proteins thrombomodulin and CD31 [28], the secretory 443 proteins vWF and TFPI require Sec61-dependent co-translational translocation into the ER 444 lumen to complete their biosynthesis, processes that are inhibited by mycolactone [24, 25]. In 445 446 in vitro model systems, the mycolactone concentration is uniform, whereas in BU skin lesions 447 the situation is more complicated, but where mycolactone is present at high enough concentrations, depletion of these Sec61-dependent molecules should also occur as the 448 process is conserved amongst diverse cell types. The variations in endothelial marker 449 450 expression seen in different specimens and sections from the same specimen may therefore reflect local variations in mycolactone concentration. However, while there is much evidence 451 for mycolactone within BU lesions [10, 56], these currently lack the spatial resolution to 452 understand exactly how much mycolactone is present at specific sites. 453

454

It is clear from our data that in the complex structure of the disordered skin in BU that there 455 456 was less than expected correlation between loss of endothelial transmembrane proteins, based on Sec61 inhibition alone. For instance, while many vessels lost both thrombomodulin 457 and vWF, some had lost expression of one marker but not the other. Since it was recently 458 459 shown that IL-1 β is present in BU skin lesions also with variable intensity across biopsy samples [45], we tested the hypothesis that this may add an additional layer of complexity in 460 the *in vivo* setting. We showed that mycolactone and IL-1β have an additive effect *in vitro*, 461 suggesting that the variation in marker expression could be caused by the cumulative effect 462 of local mycolactone and IL-1B. In this context, it is also worth noting that the distance between 463

our serial tissue sections for these markers is 24 μm inclusive and given the focal nature of
the staining for the same markers across the section (see Fig S2A), this could also be a
contributing factor.

467

These BU patients showed widespread changes to the localisation of vWF in skin punch 468 biopsies, with only a minority of vessels in defined regions displaying a normal expression 469 pattern. In healthy tissue, vWF is expressed solely in endothelial cells, and is found contained 470 471 within organelles called Weibel-Palade bodies (WBPs), which also contain a variety of other components regulating inflammation as well as vascular modulators [57]. Endothelial cells 472 473 respond rapidly upon activation by a variety of so-called secretagogues to exocytose their 474 WBP, upon which the vWF forms multimeric strings of molecules whose normal function is to capture platelets [58]. It is possible that WBP exocytosis explains the pattern we observed, 475 particularly in immune cell infiltrated regions, where vWF was lost from endothelial cells and 476 477 instead observed in the adjacent intravascular space. This pattern of expression has been previously reported in the dermal vasculature of patients with malignant melanoma [59] as 478 well as alveolar septa and large blood vessels of patients with malaria-associated acute 479 respiratory distress syndrome [37]. In melanoma vasculatures, CD42⁺ platelet aggregates 480 were also seen bound to intravascular vWF fibres [59], due to an endothelial glycocalyx 481 shedding-dependent process [60]. We did not observe platelet aggregates in these vessels in 482 our BU patients, although we cannot completely rule out that this is a technical limitation of 483 the antibody used to detect them [61]. 484

485

Another haemostatic factor with a grossly abnormal expression pattern was the extrinsic pathway initiator TF, which plays a critical role in both fibrin generation and wound repair [62]. Exposure of TF to blood is sufficient to initiate clotting, due to its cofactor activity in the activation of factors IXa and Xa by factor VIIa [63]. Consequently, TF expression in the skin is normally restricted to the epidermis and the adventitia surrounding larger vessels as a so-

491 called "haemostatic envelope" [63], and its activity is usually tightly regulated by an inhibitor, 492 TFPI [33]. Changes in TF expression have been reported in many inflammatory thrombotic 493 conditions [62, 64], as well as in infections such as tuberculosis [65, 66]. Myeloid cells do not 494 normally express TF, but during *M. tuberculosis* infection, TF expression is observed in 495 macrophages along with conspicuous fibrin deposition within granulomas [66, 67]. Mice 496 genetically altered to have low TF expression [65] or TF deficiency in myeloid cells [67] do not 497 show these changes.

498

499 Whether the endothelium can be a cellular source of the TF in pathogenic conditions remains highly controversial [62, 68]. It is well-established that inflammatory agents such as 500 501 lipopolysaccharide, oxidized low density lipoprotein and IL-1 β can induce TF mRNA and 502 protein expression in monocytes and macrophages both in vitro and in vivo [69-71]. On the other hand, while endothelial cells can be induced to express TF in vitro in response to 503 504 lipopolysaccharide and IL-1 β [42, 72, 73] the evidence that this takes place *in vivo* as part of a pathophysiological process is not so clear. For instance, endothelial-specific TF-knockout 505 mice display little influence over pathogenesis in a range of disease models [62, 74]. Much 506 evidence supports a view that procoagulant TF always arises via activated mononuclear cells 507 and that the detection of TF in other cells is a consequence of microparticle uptake [62, 75]. 508 Indeed, early reports that eosinophils could express TF following activation [76] were more 509 recently shown to be explained by their uptake of monocyte-derived microparticles [68]. While 510 this is a highly complex and also controversial area, many cell types including endothelial cells, 511 512 platelets, and monocytes/macrophages have all been shown to be capable of producing TFbearing microparticles in vitro, but monocyte-derived microparticles have been shown to be 513 the most thrombogenic [77]. As well as providing the extrinsic clotting pathway initiator TF, 514 microparticles are also thought to promote coagulation by providing a rich negatively charged 515 516 surface for the amplification of the coagulation cascade at their location [62]. The presence of 517 circulating TF-bearing microparticles has been reported in patients with cancer-associated

thrombosis [78], venous thromboembolism [79], cardiac bypass surgery [80], Behçet's disease
[81] and sepsis [82].

520

In the BU patients we investigated, epidermal expression of TF was not altered, but within the 521 522 dermis and subcutis extremely disordered TF expression was observed. In stark contrast to healthy skin, even in the pre-defined regions containing non-necrotic vessels, TF was detected 523 in the endothelial cells of >60% of tracked vessels, as well as in infiltrating cells in five patients 524 525 with either granular, or one patient with whole-cell, staining. This finding, reminiscent of inflammatory thrombotic conditions, such as sepsis and atherosclerosis [62, 64, 68], was 526 527 surprising because of mycolactone's well-characterised immunosuppressive and anti-528 inflammatory effects [56]. Once again, IL-1β may play an important role here. We speculate 529 that the TF⁺ endothelial cells and presumptive eosinophils we observed could have arisen by uptake of TF-bearing microparticles induced by IL-1 β within the lesions. It is unlikely that TF 530 531 in the endothelium has much influence over disease progression in these BU patients, as fibrin deposition was little altered around these vessels even when the anticoagulant 532 thrombomodulin was also lost from the endothelial cell surface. On the other hand, we 533 observed TF⁺ cells (presumably eosinophils) in necrotic and, more rarely, regions of BU 534 lesions containing plentiful non-necrotic vessels, where fibrin was seen intensively in tissues. 535 Notably, eosinophils have also been reported as the cellular source of TF seen in another skin 536 condition, chronic urticaria [83]. It is also possible that some of the infiltrating TF⁺ cells we 537 observed are activated macrophages that have been induced to express TF. M. ulcerans 538 infection is known to include a phase where macrophages are transiently infected with bacteria 539 [84], and the death of these cells due to the cytotoxic effects of mycolactone could conceivably 540 be another source of microparticles. Whether microparticles of any origins play an important 541 role in BU will be the subject of future investigations. 542

543

544 The strongest association we observed with fibrin deposition was diffuse TF staining extending away from larger vessels, up to 200 µm into tissue. A key question that arose was; how do TF 545 546 and the other plasma clotting factors required to produce thrombin and consequently process 547 fibrinogen to fibrin access these sites? Using an *in vitro* vascular permeability assay, we 548 showed that mycolactone potentiates the passage of 70 kDa-size dextran through monolayers 549 of both HDMECs and HDLECs. Given that adhesion molecules such as CD31 [85], 550 thrombomodulin [86, 87] and vascular endothelial cadherin are essential regulators for 551 endothelial tight junctions, and these proteins are downregulated by mycolactone [28], a 552 disturbed endothelial physical barrier between plasma and tissue could be an unavoidable phenotype in BU. A leaky vasculature is well-established to result in increased immune cell 553 invasion, as well as allowing plasma components and fluids to enter tissue [88, 89]. Hence, 554 the disrupted physical barrier may initiate a clotting cascade as blood-borne clotting factors 555 556 engage with their sub-endothelium located binding partners or activators [90].

557

Inflammatory cytokines are known to affect both microvascular and lymphatic endothelial 558 barriers and augment vascular permeability [88, 91], and this can cause tissue oedema in 559 many disease conditions [29, 88, 91]. In BU, oedematous forms are seen in around 5% of 560 patients [92]. Further work will be required to establish how early in the infection process 561 vascular permeability increases, and to understand whether it has a direct impact on M. 562 ulcerans growth. Mycolactone's effect on vascular permeability in vitro occurred much earlier 563 (within 24 hours) than its cytotoxic effects (more than 72 hours in HDMECs) and at an 564 extremely low dose (10 ng/mL), even lower in the presence of small amounts of IL-1β. 565 Furthermore, while increased vascular permeability is a common strategy used by innate host 566 defence systems to fight against invading microorganisms, many pathogens also target cell-567 cell junctions in order to cross the barrier and colonise in tissues. Interestingly, Mycobacterium 568 569 marinum, a close genetic relative of M. ulcerans, targets vascular integrity to aid its multiplication in granulomas [89]. 570

571

Taken together, both our cell-based studies and histopathological analysis in patient 572 specimens illustrate a hypercoagulative microenvironment that develops during BU disease 573 574 progression. It seems likely that the fibrin deposition seen in BU skin punch biopsies is not driven by platelet aggregation; instead, it is likely to be the consequence of factor VIIa 575 engaging with sub-endothelial TF as the endothelial cell monolayer integrity is disturbed, 576 577 exacerbated by the loss of its natural inhibitor TFPI. We have not yet analysed any potential contribution of the intrinsic clotting pathway; therefore, this cannot be excluded. A correct 578 balance of the TF-driven coagulation cascade and subsequent fibrin formation is critical in 579 wound healing [93]. Hence, application of anticoagulants along with antibiotics could help 580 581 neutralise the pro-thrombotic phenotype seen in BU patient skin lesions, and ultimately improve healing rate. Of note, complementary anticoagulant heparin alongside standard anti-582 tubercular antibiotics treatment has been previously employed to treat a case of facial BU. In 583 this patient, facial oedema was reversed by heparin intravenous injection [94], suggesting 584 585 lowering haemostatic status may attenuate BU disease progression.

586 Materials and Methods

587

588 Ethics statement

Ethical approval for analysing BU patient punch biopsies was obtained from the 589 590 Ethikkommission beider Basel, Basel, Switzerland and the provisional national ethical review board of the Ministry of Health Benin (N IRB00006860) as well as from the Cameroon National 591 Ethics Committee and the Ethics Committee of the Heidelberg University Hospital, Germany 592 (ISRCTN72102977). A favourable ethical opinion for analysing normal human skin was given 593 by Faculty of Health and Medical Science Ethics Committee of the University of Surrey (1174-594 FHMS-16). The normal human skin samples were collected by the Whiteley Clinic, Guildford, 595 596 Surrey or were purchased from AMS Biotechnology. Written informed consent was obtained 597 from adult patients or the guardians of child patients. The research related to human tissues 598 complies with the ethical processes of University of Surrey.

599

600 Histological analysis of human skin samples

Buruli ulcer punch biopsies (4 mm) were collected previously [95] and reanalysed for the 601 current study. The biopsies from 4 male and 4 female patients included lesions on both the 602 603 upper and lower extremities, from all WHO lesion categories [1]. Clinical features of these 604 patients are summarised in Table 1. In BU patients displaying ulcerated lesions, punch biopsies were taken 1 cm inside the outer margin of the induration surrounding the ulcer. 605 Otherwise, punch biopsies were collected from the non-ulcerated centre of the skin lesions. 606 After removal, tissues were fixed in 10% neutral buffered formalin, transported, embedded in 607 608 paraffin and sectioned. The normal human skin tissue blocks were made from 4 mm punch biopsies collected by The Whiteley Clinic or surgical removal specimens (< 1cm²) collected by 609 610 AMS Biotechnology-collaborated research clinical centres.

612 Nine serial tissue sections of each patient were (immuno-)histochemically stained in the following order: haematoxylin-eosin, fibrin, thrombomodulin (CD141), CD61, CD31 (Platelet 613 endothelial cell adhesion molecule; PECAM-1), SMA (perivascular cell marker), Ziehl-614 Neelsen, TF and vWF. For immunohistochemical staining, 5-µm skin tissue sections were 615 616 deparaffinised, endogenous peroxidase guenched, epitope unmasked (either in preheated pH 617 6 citrate buffer or treated with proteinase K, DAKO) and blocked with normal horse serum (Vector Laboratories). The tissue sections were incubated with primary antibody overnight at 618 619 4°C and biotin-conjugated horse anti-mouse/ rabbit IgG (Vector Laboratories) for 30 minutes 620 at room temperature. Primary antibodies were as follows: CD31 (M0823, DAKO), 621 thrombomodulin (M0617, DAKO), SMA (NCL-SMA, Novocastra), CD61 (M0753, DAKO), vWF (ab6994, Abcam), TF (TF218; generous gift from Professor Wolfram Ruf, Scripps Research 622 Institute) and Fibrin (59D8 [96]; generous gift from Professor Charles Esmon, Oklahoma 623 624 Medical Research Foundation). Staining was performed using VECTASTAIN Elite ABC kit and Vector NovaRED peroxidase substrate (Vector Laboratories). Counterstaining was performed 625 with Shandon Harris Haematoxylin (Thermo Fisher Scientific). Anti-TF and vWF antibodies 626 and their respective matched isotype controls were introduced to healthy skin tissue slides to 627 628 rule out unspecific signals. High resolution images of all slides were scanned using either Aperio slide scanner (Leica Biosystems), Pannoramic digital slide scanners (3DHISTECH) or 629 Hamamatsu slide photometry system (Hamamatsu Photonics). Scanned images were further 630 analysed using ImageScope software (Leica Biosystems) or CaseViewer (3DHISTECH). In 631 632 some cases, photographs were taken with Micropix microscope camera (acquisition software 633 Cytocam) attached to a Yenway CX40 laboratory microscope (Micropix).

634

635 Vessel identification and marker analysis

Regions of BU punch biopsy samples containing as many non-necrotic blood vessels as
possible were defined by a pathologist prior to the start of analysis. This decision was made
based on the number of blood vessels present that were positive for SMA or CD31 and

639 whether there was any submacroscopic appearance of coagulative necrosis present in the 640 corresponding H&E section. Two patient biopsies showed two distinct regions that contained 641 plentiful non-necrotic blood vessels, therefore a total of ten representative areas were analysed for each biomarker. Once the regions were chosen, all blood vessels within them 642 643 were analysed, regardless of whether nearby tissue displayed local signs of necrosis, in order 644 to facilitate an unbiased analysis. Throughout this manuscript, we refer to these as "pre-645 defined" regions. Vessels within these pre-defined regions were initially identified by 646 morphology and positive staining for SMA using the region of interest (ROI) tool on NIS Elements Basic Research (Nikon, Tokyo, Japan) (version 4.6). This allowed for the same 647 vessels to be easily identified in the other sections. Any structure that had vessel morphology 648 649 and that stained positively for the known endothelial markers CD31, thrombomodulin, or vWF in their corresponding sections were also identified and then tracked in the corresponding 650 651 sections. Sweat glands stain for SMA, but do not have endothelium and do not stain for CD31, thromobomodulin or vWF [97, 98], therefore the morphology of singly SMA⁺ structures were 652 carefully considered before assigning them as vessels. Fibrin deposition and TF expression 653 pattern around these vessels, if identifiable, was categorised. Note that not every vessel could 654 655 be identified within all sections, therefore the number of vessels analysed always represents the number that could be identified through all the relevant sections, and therefore varies from 656 analysis to analysis. 657

658

To analyse fibrin deposition that was largely seen within the tissues, two different approaches were taken. First, the distance that fibrin staining extended from the basement membrane was categorised based on measurements taken with Aperio ImageScope (version 12.3.3). Vessels with no fibrin staining within 20 μ m were scored as 0. Fibrin-positive vessels received increasing scores the further the staining extended (1; <20 μ m radius, 2; 20-30 μ m radius, 3; >30 μ m radius). Second, fibrin staining around each vessel was quantified using the calibrated ruler tool of NIS Elements Basic Research (version 4.6 and 5.21.01). Here, the threshold for

666 positive staining was first defined within random images, which was then applied to all vessels.
667 Then, a 20 µm area around all vessels was measured and traced again with the ROI tool. The
668 area of each original vessel was subtracted from the area of its 20 µm radius in order to give
669 the area in which fibrin staining was to be quantified. Any staining within this was then
670 calculated as a percentage of the 20 µm area around each vessel.

671

To analyse the unusual TF staining pattern observed, TF staining intensity within 20 μm was quantified as above for fibrin using the calibrated ruler tool of NIS Elements Basic Research (version 5.21.01). In addition, the distance that the TF signal extended from the individual vessel's basement membrane was measured by CaseViewer (version 2.2).

676

677 **Reagents**

Synthetic mycolactone A/B (generous gift of Professor Yoshito Kishi, Harvard University) [99]
and its solvent control dimethyl sulfoxide (DMSO, Sigma) were used in cell-based studies.
Human recombinant IL-1β was from Gibco.

681

Cell culture and treatment

Primary human dermal microvascular endothelial cells (HDMEC; LONZA), human umbilical vein endothelial cells (HUVECs, PromoCell) and human dermal lymphatic endothelial cells (HDLEC; PromoCell) from two donors were used and cultured according to manufacturer's recommendation in Endothelial cell growth medium MV2 (PromoCell). Subconfluent cells were treated with either 10 ng/mL mycolactone or DMSO equivalent to mycolactone dose for 24 hrs or as indicated in figure legend.

690 Vascular permeability assay

691 Endothelial cells were seeded on cell culture inserts containing 0.4 (Millipore) or 1 µm pores 692 (Falcon) with a polyethylene terephthalate membrane. Cells were treated as indicated, into both the insert and receiver wells. After 24 hrs. fluorescein isothiocvanate (FITC)-conjugated 693 694 dextran (70 kDa, Millipore) was applied to each insert for 20 minutes. The fluorescence intensity of the solution in the lower chambers was then assessed by a fluorescent plate reader 695 (FLUOstar Omega, BMG Labtech) with excitation/ emission wavelength at 485/ 530 nm. 696 Fluorescence intensity was normalised to untreated control wells with an intact monolayer of 697 endothelial cells (minimum) and expressed as a percentage of subtracted value obtained from 698 699 wells where the insert had no cells (maximum).

700

701 Cell viability assay

Endothelial cells (4 x 10³ cells) were seeded onto 96-well plates and treated with a variety of doses of mycolactone the following day. Serial dilutions of mycolactone from 50 to 0.098 ng/mL or solvent control equivalent to highest mycolactone dose (0.1% DMSO) was applied to the cells; on the fifth day viability was assayed using alamarBlue Cell Viability Reagent (Invitrogen) with excitation/ emission wavelength at 560/ 590 nm by a plate reader (FLUOstar Omega, BMG Labtech). Values were normalised to the control wells treated with DMSO and are presented as survival rate (%).

709

710 Immunochemical analysis

Western blot analysis was carried out using standard techniques, following cell lysis with 1X
RIPA buffer (Sigma) supplied with proteinase inhibitor cocktail (Sigma), separation by
electrophoresis on 10% polyacrylamide gels and transfer to PVDF membranes (ThermoFisher
Scientific). Antibodies used were TM (sc-13164, Santa Cruz), TFPI (AF2974, R&D Systems)
and GAPDH (AM4300, Ambion). Immunofluorescence staining was performed on

paraformaldehyde-fixed cells after permeabilising with 0.5% Triton X-100 for 2 minutes.
Antibodies used were vWF (ab6994, abcam) and Alexa Fluor 488 goat anti-rabbit IgG (H+L)
(ThermoFisher Scientific). Nuclei were visualised with DAPI. Images were acquired with Nikon
A1M confocal laser scanning unit attached to an Eclipse Ti-E microscope.

720

To assess the TFPI protein level in conditioned medium, an in-house ELISA was performed. 721 In brief, samples or TFPI recombinant protein standards (ranging from 1000 to 8 ng/mL, 2974-722 723 PI. R&D Systems) were coated onto immunoplates (MaxiSorp, Nunc). Following overnight 724 incubation, individual wells were blocked with 1% bovine serum albumin. Antibodies used were TFPI (AF2974, R&D Systems), HRP Rabbit anti-goat IgG (H+L), and Avidin anti-HRP 725 (Invitrogen). The reaction was developed with 3, 3', 5, 5'-tetramethylbenzidine substrate 726 727 (Invitrogen), stopped by 1M H_2SO_4 and read at 450 nm by a plate reader (FLUOstar Omega, BMG Labtech). 728

To determine the effect of mycolactone on the release of vWF from Weibel-Palade bodies, 729 HDMECs were pre-incubated with DMSO or 7.8ng/mL mycolactone for 24 hours, washed 730 731 twice with serum free medium, then stimulated with 2 U/mL thrombin for 10 minutes. vWF protein levels were then quantified using an in-house vWF ELISA. Anti-human vWF antibody 732 733 (A0082, Dako) was coated onto immunoplates overnight at 4°C and blocked with 2% BSA in PBS for 1 hour at room temperature. After blocking, the plate was washed three times with 734 wash buffer (0.05% (v/v) Tween-20 in PBS), samples and standards (NIBSC) ranging from 735 1000 mIU/mL - 4 mIU/mL were added to the wells and the plate was incubated at room 736 737 temperature for 2 hours. Then, vWF was detected with HRP-conjugated rabbit anti-human vWF (P0226, Dako) followed by 3, 3', 5, 5'-tetramethylbenzidine substrate (Invitrogen), 738 stopped by 1M H₂SO₄ and read at 450 nm by a plate reader (FLUOstar Omega, BMG 739 Labtech). 740

741

742 Statistical analysis

Statistical analysis was carried out using GraphPad Prism version 8 (San Diego, USA). 743 744 Categorical data of analysed vessels was accessed using Chi-square test of association. Yate's correction for continuity was introduced to TF categorical data set as some observed 745 values were below 5. Fibrin intensity per TM⁺ or TM⁻ vessel was assessed using Mann Whitney 746 U non-parametric test. Fibrin intensity versus TF intensity or distance to BM per vessel with 747 TF seen outside of BM was assessed using D'Agostino-Pearson normality test; as data set 748 displayed a non-Gaussian distribution, correlation used the method of Spearman. Data 749 otherwise was accessed using a one-way ANOVA and Dunnett's multi-comparison test. 750 751 Unless otherwise indicated, statistical comparison for in vitro assays was vs DMSO-treated 752 controls.

753

754 Acknowledgments

We would like to thank Lucia Lozano White (University of Surrey) for preparing tissue sections from healthy human skin tissue blocks, Dr Yoshito Kishi (Harvard University, USA) for the gift of synthetic mycolactone A/B, Prof Wolfram Ruf (Scripps Research Institute) and Prof Charles Esmon (Oklahoma Medical Research Foundation) for antibodies against TF and thrombomodulin, respectively. We thank Dr Belinda Hall and Dr Jane Newcombe for critical reading of the manuscript and Prof Mark Wansbrough-Jones (St Georges University of London) for helpful discussions leading to the testing of lymphatic endothelial cells.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.04.21261598; this version posted August 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References 762

- 1. WHO BU. Buruli ulcer. Situation and trends: World Health Organization; 2019 763 [updated 16.09.2019]. Available from: 764 https://www.who.int/gho/neglected_diseases/buruli_ulcer/en/. 765 2. Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordev A, Yeboah-Manu D, et al. 766 Buruli Ulcer: a Review of the Current Knowledge. Curr Trop Med Rep. 2018;5(4):247-767 768 56.
- 769 3. Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, et al. Mapping the 770 global distribution of Buruli ulcer: a systematic review with evidence consensus. 771 Lancet Glob Health. 2019;7(7):e912-e22.
- 772 4. Agbenorku P, Edusei A, Agbenorku M, Diby T, Nyador E, Nyamuame G, et al. Buruliulcer induced disability in ghana: a study at apromase in the ashanti region. Plast 773 Surg Int. 2012;2012:752749. 774
- Simpson C, O'Brien DP, McDonald A, Callan P. Mycobacterium ulcerans infection: 775 5. evolution in clinical management. ANZ J Surg. 2013;83(7-8):523-6. 776
- 777 6. O'Brien DP, Friedman ND, McDonald A, Callan P, Hughes A, Walton A, et al. Wound 778 healing: Natural history and risk factors for delay in Australian patients treated with 779 antibiotics for Mycobacterium ulcerans disease. PLoS Negl Trop Dis. 780 2018;12(3):e0006357.
- 7. Lunn HF, Connor DH, Wilks NE, Barnley GR, Kamunvi F, Clancey JK, et al. Buruli 781 (Mycobacterial) Ulceration in Uganda. (a New Focus of Buruli Ulcer in Madi District, 782 Uganda): Report of a Field Study. East Afr Med J. 1965;42:275-88. 783
- Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular 784 8. 785 parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis. 786 2009;9(11):699-710.
- Ruf MT, Steffen C, Bolz M, Schmid P, Pluschke G. Infiltrating leukocytes surround 787 9. 788 early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria. Virulence. 2017;8(8):1918-26. 789
- 790 10. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. 791 Science. 1999;283(5403):854-7. 792
- 793 11. Pimsler M, Sponsler TA, Meyers WM. Immunosuppressive properties of the soluble 794 toxin from Mycobacterium ulcerans. J Infect Dis. 1988;157(3):577-80.
- 795 12. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant 796 plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A. 2004;101(5):1345-9. 797
- 798 13. George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect 799 800 Immun. 2000;68(2):877-83.
- 801 14. Ogbechi J, Hall BS, Sbarrato T, Taunton J, Willis AE, Wek RC, et al. Inhibition of 802 Sec61-dependent translocation by mycolactone uncouples the integrated stress 803 response from ER stress, driving cytotoxicity via translational activation of ATF4. Cell 804 Death Dis. 2018;9(3):397.
- Morel JD. Paatero AO. Wei J. Yewdell JW. Guenin-Mace L. Van Haver D. et al. 805 15. Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive 806 Stress Signature. Mol Cell Proteomics. 2018;17(9):1750-65. 807
- 16. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, et al. Selective 808 809 suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med. 2007;204(6):1395-403. 810
- Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, et al. 811 17. 812 Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell 813 Microbiol. 2005;7(8):1187-96. 814

medRxiv preprint doi: https://doi.org/10.1101/2021.08.04.21261598; this version posted August 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

815 18. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactonemediated inhibition of tumor necrosis factor production by macrophages infected with 816 817 Mycobacterium ulcerans has implications for the control of infection. Infect Immun. 818 2007;75(8):3979-88. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The 819 19. inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell 820 821 cytokine production and NF-kappa B function. J Immunol. 1999;163(7):3928-35. 20. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits 822 823 monocyte cytokine production by a posttranscriptional mechanism. J Immunol. 2009;182(4):2194-202. 824 Hall BS, Hill K, McKenna M, Ogbechi J, High S, Willis AE, et al. The pathogenic 825 21. 826 mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends 827 on blockade of protein translocation into the ER. PLoS Pathog. 828 2014;10(4):e1004061. 829 22. Gerard SF, Hall BS, Zaki AM, Corfield KA, Mayerhofer PU, Costa C, et al. Structure of the Inhibited State of the Sec Translocon. Mol Cell. 2020;79(3):406-15 e7. 830 831 23. Baron L, Paatero AO, Morel JD, Impens F, Guenin-Mace L, Saint-Auret S, et al. Mycolactone subverts immunity by selectively blocking the Sec61 translocon. J Exp 832 Med. 2016;213(13):2885-96. 833 24. McKenna M, Simmonds RE, High S. Mechanistic insights into the inhibition of Sec61-834 835 dependent co- and post-translational translocation by mycolactone. J Cell Sci. 836 2016;129(7):1404-15. 837 25. McKenna M, Simmonds RE, High S. Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis. J Cell Sci. 838 2017;130(7):1307-20. 839 26. Grotzke JE, Kozik P, Morel JD, Impens F, Pietrosemoli N, Cresswell P, et al. Sec61 840 blockade by mycolactone inhibits antigen cross-presentation independently of 841 842 endosome-to-cytosol export. Proc Natl Acad Sci U S A. 2017;114(29):E5910-E9. 27. Lang S, Pfeffer S, Lee PH, Cavalie A, Helms V, Forster F, et al. An Update on Sec61 843 Channel Functions, Mechanisms, and Related Diseases. Front Physiol. 2017;8:887. 844 Ogbechi J, Ruf MT, Hall BS, Bodman-Smith K, Vogel M, Wu HL, et al. Mycolactone-845 28. Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with 846 847 Fibrin Deposition in Buruli Ulcer Lesions. PLoS Pathog. 2015;11(7):e1005011. 29. 848 Cahill PA, Redmond EM. Vascular endothelium - Gatekeeper of vessel health. Atherosclerosis. 2016;248:97-109. 849 850 30. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc 851 Disord. 2015;15:130. Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting 852 31. cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326-36. 853 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The 854 32. endothelial cell protein C receptor augments protein C activation by the thrombin-855 thrombomodulin complex. Proc Natl Acad Sci U S A. 1996;93(19):10212-6. 856 857 33. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934-43. 858 Marcum JA, Atha DH, Fritze LM, Nawroth P, Stern D, Rosenberg RD. Cloned bovine 859 34. 860 aortic endothelial cells synthesize anticoagulantly active heparan sulfate 861 proteoglycan. J Biol Chem. 1986;261(16):7507-17. McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF. Weibel-Palade 862 35. bodies at a glance. J Cell Sci. 2017;130(21):3611-7. 863 36. Koerdt S, Rohleder NH, Rommel N, Nobis C, Stoeckelhuber M, Pigorsch S, et al. An 864 expression analysis of markers of radiation-induced skin fibrosis and angiogenesis in 865 wound healing disorders of the head and neck. Radiat Oncol. 2015;10:202. 866 37. Pham TT, Punsawad C, Glaharn S, De Meyer SF, Viriyavejakul P, Van den Steen 867 868 PE. Release of endothelial activation markers in lungs of patients with malariaassociated acute respiratory distress syndrome. Malar J. 2019;18(1):395. 869

 Miettinen M, Lindenmayer AE, Chaubal A, Endothelial cell markers CD31, CD34, and BNH9 antibody to H and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7(1):82-90. Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin alphallbbeta3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):28. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 91917;8(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of dema formation. Lymphat Res Biol. 2008;6:3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Burrul ilder pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. C			
 the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7(1):82-00. Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin alphallbbeta3: signal transduction, regulation, and its therapeutic targeting. J Hernatol Oncol. 2019;12(1):26. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-Tbeta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphatematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2006;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Biod. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. Moxon CA, Wassmer SC, Miner DA, Jr, Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation toparasit	870 871	38.	Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigensevaluation of their specificity and sensitivity in
 Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin alphaltlbbeta3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):26. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2008;6:3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Many J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Photog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;1015(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-571. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Minne DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein G recepto	872 873		the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7(1):82-90.
 signaf transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):26. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhimann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J. Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombondulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2013;2(3):549-571. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS	874	39.	Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin alphallbbeta3:
 Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPlalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, iymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichman A, Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of nuclear factor-kappa B. Blood. 2006;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Miner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(6):842-51. Turmer L, Lavstsen T, Berger	875 876		signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol.
 Novolny Wr. Patiner M., Win PC, Brüze Soy, J., Mieland J.F., Pulnikauth and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPlalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhimann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-Ibeta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphate Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctons: Molecular control of edema formation. Lymphate Endothelial Cell Junctons: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willehrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulat	8/0 770	40	2019,12(1).20. Nevetav WE Delmier M. Wun TC, Proze C.L. Ir, Miletich ID, Durification and
 1991;78(2):394-400. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-Ibeta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of dedma formation. Lymphatic Endothelial Cell Junctions: Molecular Control of dedma formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the L-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombondulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein T receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African chidren. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severer malaria is associated with parasite binding to endothelial p	877 878	40.	properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood.
 Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-67. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Misiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Miner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. T	879		1991;78(2):394-400.
 Haemost. 2005;3(12):2677-83. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the L-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16((12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African chidren. Blood. 2013;122(5):442-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;48(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccaloschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scher N,	880	41.	Piro O, Broze GJ, Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb
 Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphadmess Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turmer L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulceran	881		Haemost. 2005;3(12):2677-83.
 Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomdulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. Moxon CA, Wassmer SC, Miner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C neceptors links coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Miner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in creebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Soph GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45	882	42.	Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr.
 endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turmer L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDDcont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v: 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli	883		Interleukin-1beta induced vascular permeability is dependent on induction of
 Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and molecular control of edema formation. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turmer L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avrill M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Soph GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. Th	884		endothelial tissue factor (TF) activity. J Transl Med. 2005;3:37.
 molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in creerbar malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer formation. J Clin Invest. 2013;12(4):1501-12. Sarto FS, Phillips R, Wansbrough-Jones M, Simmon	885	43.	Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and
 Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kapa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avrill M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-C	886		molecular control of edema formation. Lymphat Res Biol. 2008;6(3-4):123-37.
 Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. Szavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;0: (66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;0: (12):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.	887	44.	Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions:
 Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al. Mycolactone toxin induces an inflammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxn CA, Wassmer SC, Miner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et	888		Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509.
 Mycolactone toxin induces an infammatory response by targeting the IL-1beta pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 20	889	45.	Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al.
 pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog. 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmon	890		Mycolactone toxin induces an inflammatory response by targeting the IL-1beta
 2020;16(12):e1009107. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role	891		pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog.
 Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis	892		2020:16(12):e1009107.
 Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. <	893	46.	Sohn RH. Deming CB. Johns DC. Champion HC. Bian C. Gardner K. et al.
 mediated by activation of nuclear factor-kappa B. Blood. 2005;105(10):3910-7. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012;v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	894		Regulation of endothelial thrombomodulin expression by inflammatory cytokines is
 Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	895		mediated by activation of nuclear factor-kappa B. Blood, 2005;105(10):3910-7.
 2018;2(3):549-57. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	896	47	Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost
 Long(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(897		2018-2(3):549-57
 Key 2000;13(3):470-511. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	898	48	Cunningham MW Pathogenesis of group A streptococcal infections. Clin Microbiol
 49. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. 50. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. 51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. 52. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	899	10.	Rev 2000:13(3):470-511
 Kinstella and von Willebrand factor binding protein to modify the coagulation coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	900	49	McAdow M Missiakas DM Schneewind O Stanhylococcus aureus secretes
 bit cascade and establish host infections. J Innate Immun. 2012;4(2):141-8. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	901	10.	coagulase and yon Willebrand factor binding protein to modify the coagulation
 Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	902		cascade and establish host infections. I Innate Immun 2012;4(2):141-8
 Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	903	50	Moxon CA Wassmer SC Milner DA Jr Chisala NV Taylor TE Sevdel KB et al
 sequestration in cerebral malaria in African children. Blood. 2013;122(5):842-51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	904	00.	Loss of endothelial protein C receptors links coagulation and inflammation to parasite
 51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. 52. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	905		sequestration in cerebral malaria in African children Blood 2013:122(5):842-51
 malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5. 52. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	906	51	Turner L. Laystsen T. Berger SS. Wang CW. Petersen, JF. Avril M. et al. Severe
 2013;498(7455):502-5. 52. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	907	01.	malaria is associated with parasite binding to endothelial protein C receptor. Nature
 diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer). 2012:v, 66 p. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	908		2013·498/7455)·502-5
 2012:v, 66 p. 2012:v, 66 p. 2avattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	900 900	52	diseases WDocont Treatment of Mycobacterium ulcerans disease (Buruli I IIcer)
 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	010	52.	2012 v 66 n
 Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	011	53	Zavattaro E. Boccafoschi E. Borgogna C. Conca A. Johnson RC. Sonoh GE. et al.
 Apoptosis in Buruli uicer: a clinicopathological study of 43 cases. Histopathology. 2012;61(2):224-36. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	012	55.	Apontosis in Buruli ulcor: a cliniconathological study of 45 cases. Histonathology
 513 2012,01(2).224-30. 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	012		$2012.61(2).224_36$
 54. Dierr R, Scherr R, Ruhm, Dangy JF, Gersbach P, Geriniger M, et al. The Mactolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	014	54	Biori P. Schorr N. Puf MT. Dangy IP. Corsbach P. Cohringer M. et al. The Macrolide
 Inhibition of mTOR. ACS Chem Biol. 2017;12(5):1297-307. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29. 	914 015	54.	Taxin Mucalactana Bramatas Rim Danandant Apantasis in Ruruli Illear through
 916 Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, 918 Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins 919 underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. 920 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of 921 mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans 922 infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	915		Inhibition of mTOP, ACS Chom Piol, 2017;12(5):1207, 207
 S5. Guenn-Mace L, Veyron-Chunet R, Thoulouze Mi, Romet-Lemonne G, Hong H, Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	910	EE	Cuppin Mass L. Vovran Churlet P. Thoulouza MI. Domat Lamonna C. Hang H.
 Leadiay PF, et al. Mycolactone activation of Wiskott-Aldren syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;123(4):1501-12. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	917	55.	Leadley DE et al. Myselectore estivation of Wiekett Aldrich eyedrome proteine
 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29. 	010 910		Leaviay FF, et al. Wyouldouble activation of Wiskott-Aldrich Syndrome proteins
920 56. Sarro FS, Phillips K, Wansbrough-Jones M, Simmonds RE. Recent advances: role of 921 mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans 922 infection/Buruli ulcer disease. Cell Microbiol. 2016;18(1):17-29.	919	50	underprins buruit dicer formation. J Clin Invest. 2013;123(4):1501-12.
921 mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans 922 infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29.	920	JD.	Sano FS, Phillips R, Wansbrough-Jones W, Simmonds KE. Recent advances: fole of
	921 922		infection/Buruli ulcer disease. Cell Microbiol. 2016:18(1):17-29

923 924 925	57.	Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plastici of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006:26(5):1002-7.		
926	58.	Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional		
927	50	Bauer AT Suckau I Frank K Desch A Goertz I Wagner AH et al von Willebrand		
929	55.	factor fibers promote cancer-associated platelet aggregation in malignant melanoma		
930	00	of mice and humans. Blood. 2015;125(20):3153-63.		
931	60.	Kalagara I, Moutsis I, Yang Y, Pappelbaum KI, Farken A, Cladder-Micus L, et al.		
932 933		endothelium. Blood Adv. 2018;2(18):2347-57.		
934	61.	Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane		
935 936		glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985:260(20):11107-14.		
937	62.	McVev JH. The role of the tissue factor pathway in haemostasis and beyond. Curr		
938	•=-	Opin Hematol. 2016;23(5):453-61.		
939 940	63.	Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108(5):1447-52.		
941	64.	Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler Thromb.		
942		2015;22(6):543-9.		
943	65.	Kothari H, Keshava S, Vatsyayan R, Mackman N, Rao LV, Pendurthi UR. Role of		
944		tissue factor in Mycobacterium tuberculosis-induced inflammation and disease		
945		pathogenesis. PLoS One. 2014;9(12):e114141.		
946	66.	Kothari H, Rao LV, Vankayalapati R, Pendurthi UR. Mycobacterium tuberculosis		
947		infection and tissue factor expression in macrophages. PLoS One. 2012;7(9):e45700.		
948	67.	Venkatasubramanian S, Tripathi D, Tucker T, Paidipally P, Cheekatla S, Welch E, et		
949		al. Tissue factor expression by myeloid cells contributes to protective immune		
950		response against Mycobacterium tuberculosis infection. Eur J Immunol.		
951		2016;46(2):464-79.		
952	68.	Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and		
953	00	sepsis. Thromb Res. 2010;125 Suppl 1:S70-3.		
954	69.	Anamed J, Niessen F, Kurokawa T, Lee YK, Bhattacharjee G, Morrissey JH, et al.		
955		demain in ondetexemia. Blood, 2007:109(12):5251-9		
950	70	Luvondyk IP Schabbauor GA Toncati M Holschor T Pawlinski P Mackman N		
957	70.	Genetic analysis of the role of the PI3K-Akt nathway in liponolysaccharide-induced		
950		cytokine and tissue factor gene expression in monocytes/macronhages. I Immunol		
960		2008;180(6):4218-26.		
961	71.	Owens AP, 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, et al.		
962		Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic		
963		mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122(2):558-68.		
964	72.	Chakravortty D, Kato Y, Koide N, Sugiyama T, Kawai M, Fukada M, et al. Production		
965		of tissue factor in CD14-expressing human umbilical vein endothelial cells by		
966	70	lipopolysaccharide. FEMS Microbiol Lett. 1999;178(2):235-9.		
967	73.	Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Cultured		
968		numan endotnellal cells generate tissue factor in response to endotoxin. J Clin		
969	74	Invest. 1983;71(6):1893-6.		
970	74.	Pawinski R, Mackman N. Use of mouse models to study the role of tissue factor in tumor biology. Semin Thromb Homost, 2009;24(2):192.6		
3/1 070	75	Nomura S. Shimizu M. Clinical significance of proceedulant microparticles.		
912 072	15.	Intensive Care 2015:3(1):2		
975	76	Mooshauer C. Morgenstern F. Cuvelier SI. Manukvan D. Ridzbekov K. Albrocht S. ot		
975	10.	al Ensinophils are a major intravascular location for tissue factor storage and		
976		exposure. Blood. 2007;109(3):995-1002.		

977 978 979	77.	Lipets EN, Antonova OA, Shustova ON, Losenkova KV, Mazurov AV, Ataullakhanov FI. Use of Thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation.
980		PLoS One. 2020;15(5):e0227932.
981	78.	Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-
982		derived tissue factor-bearing microparticles are associated with venous
983		thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-40.
984	79.	Mendoza CE, Brant EJ, McDermott ML, Froment A, Hu Y, Hogan SL, et al. Elevated
985		Microparticle Tissue Factor Activity Differentiates Patients With Venous
986		Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. Kidney Int
987		Rep. 2019;4(11):1617-29.
988	80.	Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ,
989		Jansen PG, et al. Cell-derived microparticles generated in patients during
990		cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96(10):3534-41.
991	81.	Khan E, Ambrose NL, Ahnstrom J, Kiprianos AP, Stanford MR, Eleftheriou D, et al. A
992		low balance between microparticles expressing tissue factor pathway inhibitor and
993		tissue factor is associated with thrombosis in Behcet's Syndrome. Sci Rep.
994		2016;6:38104.
995	82.	Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, et al. Induction of
996		microparticle- and cell-associated intravascular tissue factor in human endotoxemia.
997		Blood. 2004;103(12):4545-53.
998	83.	Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of
999		tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy
1000		Immunol. 2009;148(2):170-4.
1001	84.	Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, et al. Evidence
1002		for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun.
1003		2007;75(2):977-87.
1004	85.	Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional integrity.
1005	00	Cell Hissue Res. 2014;355(3):607-19.
1006	86.	Kawamoto E, Okamoto I, Takagi Y, Honda G, Suzuki K, Imai H, et al. LFA-1 and
1007		Mac-1 Integrins bind to the serine/threonine-rich domain of thrombomodulin. Biochem
1008	07	Biophys Res Commun. 2016;473(4):1005-12.
1009	87.	Pai VC, Lo IC, Huang YW, Tsai IC, Cheng HP, Shi GY, et al. The chondrollin suitate
1010		molety mediates thrombomodulin-enhanced adhesion and migration of vascular
1011	00	Smooth muscle cells. J Diomed Sci. 2016,25(1).14.
1012	00.	Angiogenesis, Front Immunol, 2010:10:1426
1013	90	Angiogenesis. From Infinitution. 2019, 10. 1420. Ophlara SH, Cranan MP, Boarman PW, Johnson MC, Huang J, Kontos CD, et al.
1014	09.	Informers Sin, Cionan Mix, Deerman XW, Johnson MG, Huang J, Kontos CD, et al.
1015		
1010	90	Gaertner F. Massherg S. Patrolling the vascular borders: platelets in immunity to
1017	50.	infection and cancer. Nat Rev Immunol. 2019;19(12):747-60
1010	91	Cromer WE Zawieja SD Tharakan B Childs FW Newell MK Zawieja DC The
1015	51.	effects of inflammatory cytokines on lymphatic endothelial barrier function
1020		Angiogenesis 2014.17(2):395-406
1021	92	Capela C. Sopoh GE. Houezo, IG. Findessihoue R. Dossou AD. Costa P. et al.
1022	02.	Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013). Effect of Time-Delay to
1023		Diagnosis on Clinical Forms and Severe Phenotypes. PLoS Negl Trop Dis
1025		2015:9(9):e0004005.
1026	93.	Li J. Chen J. Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol
1027		2007:25(1):9-18.
1028	94.	Kanga JM, Dion-Laine M, Kacou DE, Menan EI. [Contribution of heparin therapy in
1029		the medical treatment of Buruli ulcer apropos of 1 casel. Bull Soc Pathol Exot.
1030		2001;94(1):32-5.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.04.21261598; this version posted August 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 1031 95. Vogel M, Bayi PF, Ruf MT, Bratschi MW, Bolz M, Um Boock A, et al. Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single 1032 Center Non Comparative Clinical Trial. Clin Infect Dis. 2016;62(3):342-50. 1033
- 1034 96. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science. 1983;222(4628):1129-32. 1035
- 97. Kurata R, Futaki S, Nakano I, Fujita F, Tanemura A, Murota H, et al. Three-1036
- 1037 dimensional cell shapes and arrangements in human sweat glands as revealed by whole-mount immunostaining. PLoS One. 2017;12(6):e0178709. 1038
- Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of 1039 98. endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human 1040 1041 tissues. J Histochem Cytochem. 2006;54(4):385-95.
- 99. Song F, Fidanze S, Benowitz AB, Kishi Y. Total synthesis of the mycolactones. Org 1042 1043 Lett. 2002;4(4):647-50.

1044 <u>*M. ulcerans* confirmed (n = 8)</u>

Age (years)		12 (7-70)
Type of lesion	Ulcerative	6 (75%)
	Plaque	2 (25%)
WHO category	1	2 (25%)
	2	4 (50%)
	3	2 (25%)
Location	Upper extremities	4 (50%)
	Lower extremities	4 (50%)

1045

1046 **Table 1. Clinical features of analysed Burui ulcer patients.** Category 1: a single lesion <

1047 5 cm in diameter; Category 2: a single lesion 5-15 cm in diameter; Category 3: a single

1048 lesion > 15 cm in diameter, multiple small lesions or facial lesions. Age is presented in

1049 median (with range) and the rest of data are n (%).

1051 Figure Legends

1052

Fig 1. Thrombomodulin expression and fibrin deposition in and around analysed 1053 vessels. A. Vessels in pre-defined areas of punch biopsy samples lacking submacroscopic 1054 appearance of coagulative necrosis (see methods) of 8 BU patients (6 with ulcerated lesions 1055 1056 and 2 with plague lesions) were tracked by the endothelial cell marker CD31 and perivascular 1057 cell marker SMA, analysed and categorised according to the expression of TM, CD31 and 1058 SMA. The number of vessels in each category per patient was expressed as a percentage of 1059 the total number of the vessels counted for that representative area (listed right). Patients 1060 displaying plague lesions are indicated with asterisks. The pie chart to the right shows the overall distribution of each category. B and C. The degree of fibrin deposition surrounding 1061 1062 tracked vessels in A. B represents the distribution of fibrin scores of thrombomodulin-positive 1063 (TM⁺) and thrombomodulin-negative (TM⁻) vessels. Increasing fibrin scores corresponding to 1064 increasing extension of fibrin staining and are represented by stronger colour (0: no fibrin 1065 staining with 20 μ m, 1-3 are fibrin staining in a <20, 20-30 and >30 μ m radius, respectively). The total number of the vessels analysed is shown. C. The intensity of fibrin staining within a 1066 20 µm area around each analysed vessel (TM⁻ or TM⁻) was quantified and expressed as 1067 percentage of the total analysed area for all and fibrin positive (Fib⁺) vessels. Data for 1068 individual vessels as well as median and interquartile range is shown. ***; P < 0.001. 1069

1070

Fig 2. Endothelial von Willebrand factor is downregulated in response to mycolactone 1071 and redistributes in BU lesions. A-E. Histological sections stained with antibodies against 1072 vWF (A1-2, B1-3, C6, D6 and E6), platelet glycoprotein CD61 (B4, C5, D5 and E5), SMA (C1, 1073 D1 and E1), CD31 (C2, D2 and E2), TM (C3, D3 and E3) and fibrin (C4, D4 and E4) (positive 1074 1075 staining in brown colour) and counterstained with haematoxylin in a healthy subject (A1-2) and BU patients (B, C, D and E). Scale bars as indicated. A-B. Examples of vessels with different 1076 phenotypes for vWF expression are indicated as follows; black arrows for normal expression, 1077 1078 black arrowheads for reduced expression and black stars for vessels displaying intravascular 1079 vWF staining. Outlined regions in B4 showing distinct CD61 expression patterns in defined 1080 (the upper two; crop panels see C5 & D5) and in necrotic region (the bottom one; crop panel 1081 see E5). **C-D.** Examples of vessels with different phenotypes in pre-defined areas of BU punch 1082 biopsy samples lacking submacroscopic appearance of coagulative necrosis (see methods) are indicated as follows; purple arrows are SMA+CD31-TM-, blue arrows are SMA+CD31+TM-, 1083 1084 and asterisks are SMA+CD31+TM+ vessels. E. An example of a CD61+ vessel displaying fibrin 1085 deposition in the necrotic subcutis is indicated with a red arrow. F. The overall distribution of

1086 vWF staining patterns in all patients (top panel) and vessels in immune cell-infiltrated regions 1087 (lower panel). The distribution of fibrin scores per vWF staining pattern (i.e. normal, 1088 intravascular and vWF⁻) is represented by pie charts with the total analysed vessel number shown. Increasing fibrin scores corresponding to increasing extension of fibrin staining are 1089 represented by darker colour (0; no fibrin staining with 20 μ m, 1-3 are fibrin staining in a <20, 1090 20-30 and >30 µm radius, respectively). **G & H.** Primary endothelial cells were treated with 1091 10 ng/mL of mycolactone (MYC), 0.02% DMSO or untreated (Ctrl) for 24 hours. G. HUVECs 1092 were fixed, permeabilised and immunostained with anti-vWF antibody. vWF-containing 1093 1094 granules are shown in green and nuclei stained with DAPI (blue). Scale bar = 50 µm. Scatter plot showing vWF-positive granules per cell in each condition. ****; *P* < 0.0001. **H.** HDMECs 1095 were treated with 2 U/mL thrombin to induce exocytosis of Weibel-Palade bodies. The 1096 concentration of vWF in supernatants was quantified by ELISA. nd, not detected. 1097

1098

1099 Fig 3. Tissue factor expression is altered in BU patient skin lesion. A-G. Histological 1100 sections were stained with anti-tissue factor (TF) antibody (A1-2, B5, C5, D5, E5, F5 and G5), anti-SMA antibody (B1, C1, D1, E1, F1 and G1), anti-CD31 antibody (B2, C2, D2, E2, F2 and 1101 G2), eosin (B3, C3, D3, E3, F3 and G3) or anti-fibrin antibody (B4, C4, D4, E4, F4 and G4) 1102 1103 (positive staining in a brown colour) and counterstained with haematoxylin in healthy subjects (A) or in pre-defined areas of BU punch biopsy samples lacking submacroscopic appearance 1104 of coagulative necrosis (see methods) (B-G). Scale bar = 50 μ m (20 μ m in the crop panels of 1105 D5, E5 and F5). B & C. Red arrows indicate regions of TF staining distant from the vessel 1106 basement membrane (BM). D. Asterisks label the same vessel, black arrows in the crop panel 1107 of D5 indicate examples of cells containing punctate structures staining strongly for TF. E. 1108 Black arrows indicate examples of cells staining intensively for TF throughout the cells, in 1109 regions where cells stained intensively for eosin in the H&E stain (black arrowhead). F. An 1110 orange arrow in the crop panel of F5 indicates an example of the endothelium of a small vessel 1111 1112 stained positively for TF. G. Purple arrows indicate examples in a region where multiple small 1113 vessels contained unidentified structures stained positively for TF. H. The overall distribution of vessel phenotypes for TF staining across 8 BU patients. The distribution of fibrin scores 1114 associated with each phenotype are represented as pie charts. Increasing fibrin scores 1115 1116 corresponding to increasing extension of fibrin staining are represented by stronger colour (0; no fibrin staining with 20 µm, 1-3 are fibrin staining in a <20, 20-30 and >30 µm radius, 1117 respectively). The total number of the vessels analysed is shown. 1118

1120 Fig 4. Mycolactone reduces the expression of tissue factor pathway inhibitor in 1121 endothelial cells. A. HDMECs exposed to 10 ng/mL of mycolactone (MYC) for the indicated 1122 times, 0.02% DMSO or untreated (Ctrl) were lysed and subjected to immunoblotting. TFPI immunoblot intensity was normalised according to GAPDH and untreated controls. Data from 1123 1124 3 independent experiments are presented (mean ± SEM). B. Supernatant was collected from cells treated as above for 24 hours, cell debris removed and TFPI was quantified by ELISA. 1125 Values represent the mean of three independent experiments \pm SEM. ***, P < 0.001; ****, P < 0.001; **** 1126 0.0001. 1127

1128

1129 Fig 5. Extravascular tissue factor (TF) is the primary driver of fibrin deposition in BU lesions, potentially driven by an increase in vascular permeability. A & B. Correlation 1130 1131 between the abundance of fibrin within a 20 µm radius of each vessel and the abundance of tissue factor (TF) in the same radius (A) or the distance the TF⁺ signal extended from the 1132 1133 vessel basement membrane (BM) (B) for 45 trackable vessels. r is Spearman's rank 1134 correlation coefficient for each data set. C & D. Permeability of HDMEC (C) or HDLEC (D) monolayers, on inserts with 0.4 and 1 µm pores respectively, that remained untreated (Ctrl), 1135 or were exposed to 0.02% DMSO, 2.5 or 10 ng/mL mycolactone (MYC), or 100 ng/mL IL-1β 1136 for 24 hrs. Fluorescence intensity of FITC-dextran in the receiver wells was measured and 1137 presented as a % where 100% is the value obtained from transwell lacking a cell monolayer, 1138 and 0% is untreated control wells. Values represent the mean of three independent 1139 experiments ± SEM. **, P < 0.01; ****, P < 0.0001. 1140

1141

Fig 6. IL-1ß aggravates mycolactone-driven endothelial dysfunction. HDMECs (A) or 1142 HDLECs (**B**) were exposed to different concentrations of mycolactone (MYC), and/or IL-1 β for 1143 24 hours, then lysed and subjected to immunoblotting. TM immunoblot intensity was 1144 normalised according to GAPDH and expressed relative to untreated controls. Mean 1145 expression level from 3 independent experiments are presented as a heatmap where 1146 1147 increased TM loss is represented by a paler colour. **C**. Permeability of HDMEC monolayers on inserts with 1 µm pores was quantified after exposure to mycolactone (MYC) and/or IL-1β 1148 for 24 hours. Fluorescence intensity of FITC-dextran in the receiver wells was measured and 1149 1150 presented as a % where 100% is the value obtained from transwell lacking a cell monolayer, and 0% is untreated control wells. Values represent the mean of five independent experiments 1151 ± SEM. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. 1152

1153

1155 Supporting information Captions

1156

1157 **S1 Fig. The expression patterns of haemostatic modulators in 8 BU patient skin** 1158 **biopsies.** Histological sections from 8 BU patient punch biopsies stained with eosin (H&E) or 1159 antibody against fibrin, TM, CD61, CD31, SMA, TF and vWF and counterstained with 1160 Haematoxylin. The defined regions identified by a pathologist are outlined in red; vessels in 1161 these areas were tracked and analysed for this study. Immune cell infiltration regions 1162 containing vWF seen in micro vessel lumen outlined in blue. Scale bar = 1 mm.

1163

S2 Fig. General features of BU patient skin biopsies. A. Comparison of the staining 1164 1165 patterns with the same anti-SMA or anti-fibrin antibody and conditions seen for the same 1166 punch biopsies at different positions in the tissue block. The "initial section" displays those performed for Ogbechi et al., 2015 [28], whereas the "serial section" was performed for the 1167 present work. Arrows in different colours label the same vessel identified in different tissue 1168 1169 sections. Scale bar = 500 µm. Note how the vessel phenotype can vary even over small 1170 distances. B. An example of vessel identification and labelling (in colours with individual number indicated) in serial tissue sections stained with anti-SMA and CD31 antibody. C. 1171 Mycobacterial clusters (in purple, indicated with arrows) are identified in histological sections 1172 from 2 BU patient punch biopsies with Ziehl-Neelsen staining. Scar bars as indicated. 1173

1174

S3 Fig. vWF expression in BU patient specimen and in primary HDMECs. A. Histological
sections of a healthy subject or BU patient stained with anti-vWF antibody, the respective
isotype control or secondary antibody alone and counterstained with Haematoxylin. B.
HDMECs were treated with 10 ng/mL of mycolactone (MYC), 0.02% DMSO or untreated (Ctrl)
for 24 hours. Cells were fixed, permeabilised and immunostained with anti-vWF antibody.
vWF-containing granules are shown in green and nuclei stained with DAPI (blue). Scale bar =
20 μm.

1182

S4 Fig. Tissue factor (TF) expression patterns in BU patient specimen. A. Histological sections of a healthy subject or BU patient stained with anti-TF antibody, the respective isotype control or secondary antibody alone and counterstained with Haematoxylin. B & C. Histological sections stained with Haematoxylin and eosin or antibodies against TF and fibrin and counterstained with Haematoxylin in BU patients. TF-positive activated leukocytes in

1188 necrotic subcutis (B) and structures at the edge of the haemorrhagic area (C). Scale bar as1189 indicated.

- 1190
- 1191 S5 Fig. Susceptibility of endothelial cells to mycolactone. Cell viability of HDLECs,
- 1192 HDMECs and HUVECs exposed to a variety doses of mycolactone for 5 days was determined
- using alamarBlue assay and presented as a % where 100% is the value obtained from cells
- treated with solvent control DMSO.









Fig 3















С

Ziehl Neelsen





В

Ctrl DMSO MYC





